Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.18 | 21.39 | 35.52 | 28.32 | 33.38 | 40.01 | 40.33 | 34.18 | 39.30 | 42.96 | 60.96 | 39.84 |
| Expenses | 12.41 | 16.59 | 29.26 | 24.10 | 25.92 | 32.86 | 38.31 | 29.11 | 31.74 | 34.39 | 55.07 | 35.46 |
| Operating Profit | 5.77 | 4.80 | 6.26 | 4.22 | 7.46 | 7.15 | 2.02 | 5.07 | 7.56 | 8.57 | 5.89 | 4.38 |
| OPM % | 31.74% | 22.44% | 17.62% | 14.90% | 22.35% | 17.87% | 5.01% | 14.83% | 19.24% | 19.95% | 9.66% | 10.99% |
| Other Income | 0.00 | 0.00 | 0.00 | 2.47 | 0.00 | 0.00 | 3.68 | 2.28 | 0.00 | -0.30 | 1.02 | 2.01 |
| Interest | 0.78 | 0.83 | 0.73 | 0.73 | 0.22 | 0.84 | 1.20 | 0.98 | 1.03 | 1.11 | 1.08 | 0.57 |
| Depreciation | 1.03 | 0.45 | 0.23 | 0.45 | 1.11 | 0.50 | 0.54 | 0.50 | 0.47 | 0.52 | 1.16 | 0.90 |
| Profit before tax | 3.96 | 3.52 | 5.30 | 5.51 | 6.13 | 5.81 | 3.96 | 5.87 | 6.06 | 6.64 | 4.67 | 4.92 |
| Tax % | 22.47% | 21.31% | 15.28% | 15.43% | 12.23% | 12.91% | 22.22% | 14.48% | 9.08% | 9.79% | 4.50% | 5.08% |
| Net Profit | 3.07 | 2.76 | 4.50 | 4.66 | 5.38 | 5.06 | 3.07 | 5.01 | 5.51 | 6.00 | 4.46 | 4.67 |
| EPS in Rs | 0.17 | 0.15 | 0.20 | 0.19 | 0.21 | 0.20 | 0.10 | 0.20 | 0.21 | 0.22 | 0.15 | 0.18 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42 | 44 | 56 | 56 | 60 | 61 | 66 | 87 | 138 | 173 | 183 |
| Expenses | 37 | 42 | 52 | 52 | 53 | 56 | 61 | 70 | 121 | 150 | 157 |
| Operating Profit | 5 | 2 | 4 | 3 | 7 | 5 | 5 | 17 | 17 | 22 | 26 |
| OPM % | 11% | 5% | 7% | 6% | 11% | 9% | 7% | 20% | 12% | 13% | 14% |
| Other Income | 0 | 1 | 1 | 1 | 0 | 1 | 4 | 5 | 10 | 8 | 3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 4 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 |
| Profit before tax | 3 | 1 | 3 | 3 | 5 | 5 | 6 | 16 | 21 | 23 | 22 |
| Tax % | 13% | 42% | 26% | 27% | 20% | 23% | 23% | 20% | 15% | 10% | |
| Net Profit | 3 | 1 | 2 | 2 | 4 | 4 | 5 | 13 | 18 | 21 | 21 |
| EPS in Rs | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.28 | 0.58 | 0.80 | 0.86 | 0.76 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 24% | 38% | 24% | ||
| Compounded Profit Growth | % | 38% | 64% | 14% | ||
| Stock Price CAGR | 4% | 9% | 3% | -12% | ||
| Return on Equity | 9% | 10% | 10% | 11% |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 18 | 23 | 23 | 24 |
| Reserves | 18 | 19 | 21 | 23 | 27 | 31 | 62 | 148 | 164 | 198 |
| Borrowings | 4 | 2 | 5 | 5 | 7 | 10 | 1 | 6 | 10 | 36 |
| Other Liabilities | 14 | 16 | 13 | 16 | 12 | 14 | 51 | 54 | 59 | 90 |
| Total Liabilities | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 349 |
| Fixed Assets | 16 | 16 | 16 | 15 | 14 | 14 | 74 | 56 | 60 | 61 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 13 |
| Investments | 7 | 7 | 7 | 7 | 7 | 7 | 0 | 0 | 0 | 0 |
| Other Assets | 26 | 28 | 29 | 35 | 38 | 48 | 59 | 172 | 191 | 275 |
| Total Assets | 49 | 50 | 52 | 57 | 59 | 68 | 132 | 230 | 256 | 349 |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -0 | 3 | 2 | -2 | -1 | 12 | 24 | -47 | -10 | -64 |
| Cash from Investing Activity | -1 | -1 | -1 | -0 | -0 | -2 | -38 | 19 | 3 | -5 |
| Cash from Financing Activity | 1 | -2 | 1 | -0 | 2 | -2 | 21 | 74 | 2 | 65 |
| Net Cash Flow | -0 | 0 | 2 | -2 | 0 | 8 | 6 | 46 | -5 | -3 |
| Free Cash Flow | -1 | 2 | 1 | -2 | -2 | 10 | -16 | -31 | -15 | -76 |
| CFO/OP | 13% | 190% | 55% | -52% | 1% | 242% | 505% | -274% | -39% | -274% |
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 87 | 68 | 41 | 55 | 67 | 52 | 75 | 37 | 92 |
| Inventory Days | 43 | 31 | 57 | 78 | 50 | 72 | 139 | 184 | 133 | 152 |
| Days Payable | 139 | 161 | 88 | 86 | 59 | 72 | 63 | 111 | 49 | 57 |
| Cash Conversion Cycle | -7 | -43 | 38 | 34 | 46 | 67 | 129 | 148 | 122 | 187 |
| Working Capital Days | 74 | 75 | 56 | 87 | 108 | 87 | 23 | 255 | 214 | 295 |
| ROCE % | 6% | 11% | 8% | 14% | 12% | 11% | 14% | 13% | 12% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 23.61% | 23.61% | 18.41% | 18.41% | 18.41% | 18.41% | 18.41% | 19.82% | 23.62% | 23.62% | 23.63% | 23.63% |
| Public | 76.39% | 76.39% | 81.58% | 81.57% | 81.59% | 81.58% | 81.58% | 80.17% | 76.38% | 76.39% | 76.36% | 76.38% |
| No. of Shareholders | 50,988 | 69,723 | 83,996 | 87,820 | 90,236 | 92,506 | 92,326 | 91,183 | 90,320 | 86,306 | 84,133 | 82,886 |
Fundamentals
Market Cap₹ 245 Cr.
Current Price₹ 10.1
Stock P/E13.0
Book Value₹ 9.16
ROCE11.8 %
ROE10.5 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)24%
Compounded Profit Growth (TTM)14%
Consolidated figures.
Valuation
Market capRs 223 Cr
Enterprise valueRs 206 Cr
P/E (TTM)12.16x
Price to book1.00x
Price to sales1.22x
EV / EBITDA7.09x
EV / EBIT7.92x
EV / sales1.13x
Earnings yield8.22%
P/E, 3-year average16.71x
P/B, 3-year average1.44x
P/E, 5-year average18.69x
P/B, 5-year average1.52x
Profitability
Operating margin (excl. other income)12.99%
Operating margin (incl. other income)17.42%
EBITDA margin15.91%
Pre-tax margin12.18%
Net profit margin10.01%
Net margin, latest quarter10.84%
ROE10.25%
ROCE12.05%
ROA6.94%
ROE, 3-year average10.31%
ROCE, 3-year average13.55%
ROA, 3-year average7.22%
ROE, 5-year average9.65%
ROCE, 5-year average12.78%
ROA, 5-year average6.55%
ROIC (approx.)11.43%
Tax rate9.72%
Other income / net worth3.44%
Growth
Sales growth (latest year)25.26%
Profit growth (latest year)15.78%
Sales CAGR, 3 years38.08%
Sales CAGR, 5 years23.70%
Profit CAGR, 3 years62.16%
Profit CAGR, 5 years39.02%
Sales growth QoQ-34.65%
Profit growth QoQ15.51%
Sales growth YoY (latest quarter)16.56%
Profit growth YoY (latest quarter)-5.88%
Per share
EPS (TTM)Rs 0.81
EPS (latest year)Rs 0.92
EPS (latest quarter)Rs 0.19
EPS, 3-year averageRs 0.77
EPS, 5-year averageRs 0.58
Book value per shareRs 9.78
Sales per shareRs 8.05
Cash flow per shareRs -2.80
Free cash flow per shareRs -3.34
Efficiency
Asset turnover0.50x
Fixed asset turnover2.84x
Inventory turnover2.52x
Inventory days145 days
Debtor days92 days
Debtors turnover3.97x
Creditor days57 days
Cash conversion cycle187 days
Working capital days295 days
Leverage
Total debtRs 36 Cr
Cash and bankRs 52 Cr
Net debtRs -16 Cr
Debt to equity0.16x
Net debt / EBITDA-0.57x
Interest coverage6.88x
Owners' fund to total sources63.82%
Debt to assets10.31%
Cash flow
Cash from Operating Activity (latest year)Rs -64 Cr
Cash from Investing Activity (latest year)Rs -5 Cr
Cash from Financing Activity (latest year)Rs 65 Cr
Net Cash Flow (latest year)Rs -3 Cr
Free cash flow (latest year)Rs -76 Cr
FCFE (approx.: FCF + change in debt)Rs -50 Cr
Cash from ops / profit, 5 years-1.39x
Statement figures
Net sales (TTM)Rs 183 Cr
Net sales (latest year)Rs 173 Cr
Sales (latest quarter)Rs 40 Cr
Operating profit excl. other income (latest year)Rs 22 Cr
Operating profit (latest quarter)Rs 4 Cr
Other income (TTM)Rs 8 Cr
EBITDA (TTM)Rs 29 Cr
PBDT (TTM)Rs 25 Cr
Profit before tax (TTM)Rs 22 Cr
Tax (latest year)Rs 2 Cr
Net profit (TTM)Rs 18 Cr
Net profit (latest year)Rs 21 Cr
Net profit (latest quarter)Rs 4 Cr
Depreciation (TTM)Rs 3 Cr
Depreciation (latest quarter)Rs 1 Cr
Interest (TTM)Rs 4 Cr
Cost of goods sold (latest year)Rs 136 Cr
Total expenditure (latest year)Rs 150 Cr
Total income (latest year)Rs 180 Cr
Share capitalRs 24 Cr
ReservesRs 198 Cr
Shareholders' fundsRs 223 Cr
Total assetsRs 349 Cr
Net blockRs 61 Cr
Capital work in progressRs 13 Cr
InvestmentsRs 0 Cr
ReceivablesRs 44 Cr
InventoryRs 54 Cr
Other liabilitiesRs 90 Cr
Shares outstanding (crore)22.74
Ownership
Promoter holding23.63% (+3.81 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 12.2 is at the 2th percentile of its own 9.4-year range
(median 36.8, low 9.4, high 109.7).
P/B 1.00 is at the 2th percentile (median 2.53).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 531739 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -3.4% | -2.8% | -0.7 pts |
| 1 month | -24.4% | -6.8% | -17.6 pts |
| 3 months | -8.6% | -7.6% | -1.0 pts |
| 3 years | +5.3% | +14.2% | -8.9 pts |
| 5 years | +47.1% | +27.9% | +19.3 pts |
Red flags
F-score 2 of 8| explain | Weak cash conversion Cash from operations was -229% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 24% of total assets in 2026 |
| explain | Receivables outrunning sales Receivables grew 208% vs sales +25% in 2026 |
| explain | Share dilution Share count up 7% in a year, 38% in three |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹40 Cr +16.6% vs Jun 2025.
Net profit ₹5 Cr -6.8%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Gennex Laboratories Ltd?
Gennex Laboratories Ltd (531739) has a market capitalisation of Rs 245 Cr. at the 2026-10-01 close.
What is the P/E ratio of Gennex Laboratories Ltd?
Gennex Laboratories Ltd trades at a P/E of 13.0 on trailing twelve-month profit, at the 2026-10-01 close.
What were Gennex Laboratories Ltd's latest quarterly results?
In the Jun 2026 quarter, Gennex Laboratories Ltd sales was Rs 40 Cr (+16.6% vs Jun 2025) and net profit was Rs 5 Cr.